Directory of Drugs for National Basic Medical Insurance

by King & Wood Mallesons’ Compliance Group

On July 2, the National Development and Reform Commission (“NDRC”) announced that it is investigating costs and prices charged by 60 foreign and domestic drug makers. Concerned pharmaceutical manufacturers should be aware that the investigation process imposes certain rights and obligations on the manufacturers and the investigating authorities alike.
Continue Reading China’s Investigation into Drug Pricing: What You Need to Know